Disease · MONDO_0002039

cognitive disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cognitive disorder. Diseases, record MONDO_0002039. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002039

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cognitive disorder; Open Targets
Open Targets ID: MONDO_0002039; Open Targets
Other names: Cognition Disorders, Cognitive Defects, Cognitive Deficits, cognitice dysfunction; Open Targets
Disease Ontology: DOID:1561; Disease Ontology
MeSH: D019965; MeSH
NCI Thesaurus: C92196; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 49 drugs, from ClinicalTrials.gov; Open Targets

Drugs49

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEMANTINE	CHEMBL807	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BIFIDOBACTERIUM SPP.	CHEMBL4297912		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
EMOXYPINE SUCCINATE	CHEMBL6068558	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MINOCYCLINE	CHEMBL1434	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GONADORELIN ACETATE	CHEMBL1200511	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MARAVIROC	CHEMBL256907	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM BUTYRATE	CHEMBL62381	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
(+/-)NICOTINE	CHEMBL440464	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 49

See all 49 drugs

Targets113

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	4	Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptor agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Unknown	https://conductscience.org/library/genes/2057	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SLC6A3	Sodium-dependent dopamine transporter	3	Dopamine transporter inhibitor	Phase 2	https://conductscience.org/library/genes/6531	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 2	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 2	https://conductscience.org/library/genes/1141	Drugs and targets
DRD3	D(3) dopamine receptor	2	Dopamine D3 receptor agonist; Dopamine receptor agonist	Unknown	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D(4) dopamine receptor	2	Dopamine D4 receptor agonist; Dopamine receptor agonist	Unknown	https://conductscience.org/library/genes/1815	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets

1 to 10 of 113

See all 113 targets

Trials41

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02008773	A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia	Phase 2	170	2019-01-30	Schizophrenia	VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT02793687	Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy	Phase 3	150	2025-02-24	Ischemic Stroke	EMOXYPINE SUCCINATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00853580	A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1	Phase 2	146	2018-03-12	Neurofibromatosis Type 1	LOVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00453921	Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)	Not applicable	76	2018-06-07	Brain Injury	METHYLPHENIDATE	Its record names the disease	ClinicalTrials.gov
NCT00487942	Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits	Phase 2	60	2010-12-20	Schizophrenia	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT00635102	Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects	Not applicable	57	2016-12-16	Alcohol Dependence	CYCLOSERINE, GLYCINE	Its record names the disease	ClinicalTrials.gov
NCT03711500	D-serine Augmentation of Neuroplasticity	Phase 1/2	45	2022-06-14	Schizophrenia, Schizo Affective Disorder	(D)-SERINE	Its record names the disease	ClinicalTrials.gov
NCT04602221	A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine	Phase 1	40	2024-03-12	Healthy	ICLEPERTIN, LAMOTRIGINE, OSORESNONTRINE	Its record names the disease	ClinicalTrials.gov
NCT04251585	Intranasal Insulin in Parkinson's Disease	Phase 2	31	2026-02-11	Parkinson Disease	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT03172026	Maraviroc to Augment Rehabilitation Outcomes After Stroke	Phase 2/3	2	2021-08-03	Stroke	MARAVIROC	Its record names the disease	ClinicalTrials.gov

1 to 10 of 41

See all 41 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Valacyclovir vs Placebo: deaths from any cause	0 of 84	0 of 86	170	NCT02008773	Trial comparisons
Valacyclovir vs Placebo: serious adverse events	3 of 84	4 of 86	170	NCT02008773	Trial comparisons
Mexidol® vs Placebo: deaths from any cause	0 of 75	0 of 75	150	NCT02793687	Trial comparisons
Mexidol® vs Placebo: serious adverse events	1 of 75	3 of 75	150	NCT02793687	Trial comparisons
Lovastatin vs Placebo: deaths from any cause	0 of 74	0 of 70	144	NCT00853580	Trial comparisons
Lovastatin vs Placebo: serious adverse events	6 of 74	1 of 70	144	NCT00853580	Trial comparisons
Alcoholic Subjects vs Healthy Subjects: serious adverse events	0 of 27	0 of 30	57	NCT00635102	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36048943	RESULT	1	PubMed
33016677	RESULT	1	PubMed
28922590	RESULT	1	PubMed
28665371	RESULT	1	PubMed
21124304	RESULT	1	PubMed
42780868	DERIVED	1	PubMed
42606862	DERIVED	1	PubMed
37690312	DERIVED	1	PubMed
37293030	DERIVED	1	PubMed
36958998	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002039

GET https://conductscience.org/api/diseases/v1/MONDO_0002039/drugs?page=2

API reference For AI assistants